Download PDF
Arzneimittelforschung 2011; 61(12): 693-699
DOI: 10.1055/s-0031-1300589
Analgesics · Anti-inflammatories · Antiphlogistics · Antirheumatic Drugs
Editio Cantor Verlag Aulendorf (Germany)

Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry

Karthikeyan Kandasamy
1   Department of Pharmaceutical Quality Assurance Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Vasantharaju Surenahalli Gowdra
1   Department of Pharmaceutical Quality Assurance Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
,
Hariprabhu Nammalvar
2   Department of Pharmaceutics, KMCH College of Pharmacy, Kalapatti Coimbatore, India
,
Arul Kumaran Kottur S. Govindarajan
2   Department of Pharmaceutics, KMCH College of Pharmacy, Kalapatti Coimbatore, India
› Author Affiliations
Further Information

Publication History

Publication Date:
09 February 2012 (online)

    Permissions and Reprints

Abstract

A simple, highly sensitive, precise and accurate high-performance liquid chromatographic (LCMSMS) method with mass detection was developed and validated for the rapid quantification of flupirtine (CAS 75507-68-5) in rat plasma samples. The chromatographic separation was achieved with a reverse phase column (4.6 × 50 mm, 5 µ m) and the mobile phase consisted of cyanomethane and 5 mM ammonium formate buffer pH 4.5 (70:30 v/v) as eluent, at a flow rate of 0.6 mL/min. Labetalol (CAS 36894-69-6) was used as an internal standard. The effluence was ionized by positive electro-spray ionization and measured by mass spectrometry. The retention times of flupirtine and labetalol were found to be 2.16 and 1.66 min respectively. The calibration curve was linear (r2 > or = 0.99) ranging from 0.98 to 1000 ng/ml and the lower limit of quantification was 0.98 ng/ mL. Inter-day and Intra-day precision were lower than 5% (CV) and accuracy ranged from 90 to 110% in terms of percent accuracy. Mean extraction recovery was found to be above 86.5%. The method was successfully applied for evaluation of the pharmacokinetic profile of flupirtine in male Sprague-Dawley rats and validated for excellent selectivity, accuracy, precision, recovery and stability.

Key words

Electrospray ionization - Flupirtine - HPLC - Mass detection - Rat plasma - Validation
 

  • References

  • 1 Friedel HA, Fitton A. Flupirtine – a review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs. 1993; 45: 548-69
    CrossrefPubMedGoogle Scholar
  • 2 Dimpfel W, Spuler M, Nickel B. Radioelectroencephalography (Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital. Neuropsychobiology. 1986; 16: 163-8
    CrossrefPubMedGoogle Scholar
  • 3 Bleyer H, Carlsson KH, Erkel HJ, Jurna I. Flupirtine depresses nociceptive activity evoked in rat thalamus. Eur J Pharmacol. 1988; 151 (2) 259-65
    CrossrefPubMedGoogle Scholar
  • 4 Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippo-campal neurons. Br J Pharmacol. 1997; 122: 1333-8
    CrossrefPubMedGoogle Scholar
  • 5 Kornhuber J, Maler M, Wiltfang J, Bleich S, Degner D, Ruther E. Opening of neuronal K+ channels by flupirtine. Fortschr Neurol Psychiatr. 1999a;67:466-75.
    PubMed
  • 6 Kornhuber J, Belich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor antagonism by enhance Mg2+ block via activation of voltage independent potassium channels. J Neural Transm. 1999; b 106: 857-67
    CrossrefPubMedGoogle Scholar
  • 7 Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, Koe-berl DD et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol. 2002; 51: 448-66
    CrossrefPubMedGoogle Scholar
  • 8 Schröder HC, Müller WE. Neuroprotective effect of flupirtine in prion disease. Drugs Today (Barc). 2002; 49: 49-58
    PubMedGoogle Scholar
  • 9 Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wilt-fang J et al. Efficacy of flupirtine on cognitive function in patients with CJD. Neurology. 2004; 62: 714-8
    CrossrefPubMedGoogle Scholar
  • 10 Müller WE, Laplanche JL, Ushijima H, Schröder HC. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech Ageing Dev. 2000; 116: 193-218
    CrossrefPubMedGoogle Scholar
  • 11 Chen XY, Zhong DF, XU HY, Schug B, Blume H. Simultaneous determination of flupirtine and its active metabolite D-13223 by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2001; 755: 195-202
    PubMedGoogle Scholar
  • 12 Zhong D, Chen X, Gu J, Li X, Guo J. Applications of liquid chromatography-tandem mass spectrometry in drug and biomedical analyses. Clin Chim Acta. 2001; 313 (1 – 2) 147-50
    CrossrefPubMedGoogle Scholar
  • 13 Rupalla K, Cao W, Krieglstein J. Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration. Eur J Pharmacol. 1995; 294: 469-73
    CrossrefPubMedGoogle Scholar
  • 14 Hummel T, Friedman T, Pauli E, Niebch G, Borbe HO, Ko-bal G. Dose-related analgesic effects of flupirtine. Br J Clin Pharmacol. 1991; 32: 69-76
    CrossrefPubMedGoogle Scholar
  • 15 Methling K, Reszka P, Lalk M, Vrana O, Scheuch E, Sieg-mund W et al. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos. 2009; 37: 479-93
    CrossrefPubMedGoogle Scholar
  • 16 Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterizationof assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 2007; 9 (2) E117-22
    CrossrefPubMedGoogle Scholar
  • 17 Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 2007; 9 (1) E109-14
    CrossrefPubMedGoogle Scholar
  • 18 Causon R. Validation of chromatographic methods in biomedical analysis: viewpoint and discussion. J Chromatogr B Biomed Sci Appl. 1997; 689: 175-80
    CrossrefPubMedGoogle Scholar